{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rilpivirine&page=3", "query": { "intervention": "rilpivirine", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 83, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rilpivirine&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rilpivirine&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T06:45:50.082Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04979728", "title": "HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Treatment", "HIV Prevention" ], "interventions": [ { "name": "At Home Self-Collections", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2021-05-27", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04979728" }, { "nct_id": "NCT06411223", "title": "Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hiv" ], "interventions": [ { "name": "Collaborative drug therapy management model", "type": "BEHAVIORAL" }, { "name": "Cabotegravir/Rilpivirine", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-08-01", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06411223" }, { "nct_id": "NCT02165202", "title": "Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "Rilpivirine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PATH", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 136, "start_date": "2014-10", "completion_date": "2017-03-09", "has_results": true, "last_update_posted_date": "2018-08-27", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 2, "location_summary": "Newark, New Jersey • The Bronx, New York", "locations": [ { "city": "Newark", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02165202" }, { "nct_id": "NCT04973254", "title": "Improving Treatment and Retention Adherence in Nontraditional Settings", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB-RPV LA", "type": "OTHER" }, { "name": "Standard treatment within an HIV clinic", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-02-23", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973254" }, { "nct_id": "NCT02556268", "title": "Interaction With HIV Antiretroviral Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-DDI" ], "interventions": [ { "name": "Riociguat (Adempas, BAY 63-2521)", "type": "DRUG" }, { "name": "ATRIPLA", "type": "DRUG" }, { "name": "COMPLERA", "type": "DRUG" }, { "name": "STRIBILD", "type": "DRUG" }, { "name": "TRIUMEQ", "type": "DRUG" }, { "name": "Antiretroviral protease inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2016-02-23", "completion_date": "2016-12-07", "has_results": false, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 2, "location_summary": "Orlando, Florida • Boston, Massachusetts", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556268" }, { "nct_id": "NCT01252940", "title": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/RPV/TDF", "type": "DRUG" }, { "name": "PI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 482, "start_date": "2010-11", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252940" }, { "nct_id": "NCT05660980", "title": "Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Once daily CAB tablet + RPV tablet", "type": "DRUG" }, { "name": "Long acting CAB injectable + long acting RPV injectable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 90, "start_date": "2024-01-24", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Memphis, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660980" }, { "nct_id": "NCT07637942", "title": "Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV -1 Infection" ], "interventions": [ { "name": "Every 4-week long-acting injectable cabotegravir and rilpivirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2026-10-15", "completion_date": "2028-03-22", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 10, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07637942" }, { "nct_id": "NCT01495702", "title": "Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "NNRTI", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 439, "start_date": "2011-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-01-07", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495702" }, { "nct_id": "NCT07682961", "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "Cabotegravir", "type": "DRUG" }, { "name": "Rilpivirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-07-14", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-05T06:45:50.082Z", "location_count": 16, "location_summary": "San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07682961" } ] }